Drug Maker Simcere Ditches Cell Therapy to Focus on Oncology
Company sells money-losing Simgene unit for $16 million, following recent deals to commercialize two new cancer drugs in China Key Takeaways: New China licensing deals and oncology focus come amid…
Recent Articles
RELATED ARTICLES
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
- ProfoundBio discovers the joys of having a wealthy owner
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
Discover hidden China stock gems in our weekly newsletter